Many patients with Immune-Mediated Inflammatory Diseases (IMIDs) receive symptomatic treatment, which fails to address their underlying disease. The emergence of comorbidities compounds their cost of care, burdening both IMID patients and the healthcare system at large.
Patients with axial spondyloarthritis had an average of 4x higher total healthcare costs than the general population.2
Together we can assess the psoriatic patient’s journey, promote patient-focused care practices, and implement quality measures to create meaningful change.
Source
2. Walsh JA, et al, Rheumatol Ther. 2018;5(2):463-474.
Resources and Quality Measures
Inflammatory Back Pain Questionnaire
A validated screening tool adapted from ASAS Inflammatory Back Pain criteria for early identification of axial spondyloarthritis (axSpA) patients
Report highlighting EHR-integrated screening that improved early axial spondyloarthritis (axSpA) identification and helped close care gaps in community rheumatology.
